Clinical Trials on Primary Immune Thrombocytopenia (ITP) in Russian Federation

Total 197 results

GlaxoSmithKline

Completed

Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)

Purpura, Thrombocytopaenic, Idiopathic

Germany, Russian Federation
Instituto Grifols, S.A.

Completed

Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura (ITP)

Immune (Idiopathic) Thrombocytopenic Purpura

Spain, Russian Federation, United Kingdom
Novartis Pharmaceuticals

Completed

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP (TAPER)

Immune Thrombocytopenic Purpura (ITP)

Spain, Italy, Greece, Switzerland, United Kingdom, France, Turkey, Russian Federation, Brazil, Austria, Mexico, Oman, Chile, Japan, United States
Novartis Pharmaceuticals

Completed

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopenic, Idiopathic

Russian Federation
UCB Biopharma SRL

Terminated

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy2)

Primary Immune Thrombocytopenia

United States, Bulgaria, China, France, Germany, Poland, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
UCB Biopharma SRL

Terminated

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy3)

Primary Immune Thrombocytopenia

United States, China, Georgia, Germany, Hungary, Italy, Japan, Moldova, Republic of, Poland, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
UCB Biopharma SRL

Terminated

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy1)

Primary Immune Thrombocytopenia

United States, Bulgaria, France, Georgia, Greece, Hungary, Italy, Japan, Korea, Republic of, Moldova, Republic of, Poland, Romania, Russian Federation, Taiwan, Ukraine, United Kingdom
CSL Behring

Completed

Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10

Immune Thrombocytopenic Purpura

Poland, Ukraine, Germany, Russian Federation, Italy, United Kingdom
argenx

Active, not recruiting

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE+)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, United Kingdom, Ukraine
argenx

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC+)

Primary Immune Thrombocytopenia

United States, Australia, Bulgaria, China, Georgia, Greece, Italy, Japan, Poland, Portugal, Romania, Russian Federation, Thailand, Turkey, Argentina, Chile, Ireland, Jordan, Tunisia, Korea, Republic of, Mexico, New Zealand, South Africa and more
GlaxoSmithKline

Completed

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Thailand, Korea, Republic of, United Kingdom, New Zealand, Germany, Greece, Hong Kong, Pakistan, Poland, Romania, Russian Federation, Slovenia, Taiwan
argenx

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)

Primary Immune Thrombocytopenia

United States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
argenx

Completed

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
GlaxoSmithKline

Completed

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Italy, Germany, Hong Kong, Korea, Republic of, United States, Pakistan, Russian Federation, India, Czech Republic, Hungary, France
Bristol-Myers Squibb

Completed

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)

Immune Thrombocytopenic Purpura

United States, Australia, United Kingdom, Canada, Georgia, Moldova, Republic of, Poland, Russian Federation
AO GENERIUM

Enrolling by invitation

Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients

Idiopathic Thrombocytopenic Purpura

Russian Federation
GlaxoSmithKline

Completed

LENS - Long-term Eltrombopag Observational Study (LENS)

Purpura, Thrombocytopaenic, Idiopathic

United States, Bulgaria, Italy, Peru, Russian Federation, Canada, France, Germany, Hong Kong, Spain, Sweden, United Kingdom, Hungary, Poland, Ukraine, Czech Republic, India, Australia, Tunisia, Puerto Rico, Pakistan
GlaxoSmithKline

Completed

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag (RAISE)

Purpura, Thrombocytopaenic, Idiopathic

United States, Taiwan, Italy, Poland, Peru, Canada, Denmark, Germany, Slovakia, Spain, United Kingdom, New Zealand, China, Greece, Hong Kong, Russian Federation, Austria, Netherlands, Czech Republic, France, India, Ukraine, Tunisia, F... and more
Kezar Life Sciences, Inc.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP (MARINA)

Immune Thrombocytopenia | Autoimmune Hemolytic Anemia

Poland, United States, Australia, Italy, Russian Federation
Federal Research Institute of Pediatric Hematology...

Completed

Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.

Wiskott-Aldrich Syndrome

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

Wiskott-Aldrich Syndrome

Russian Federation
AO GENERIUM

Completed

Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP

Idiopathic Thrombocytopenic Purpura

Russian Federation
Sobi, Inc.

Active, not recruiting

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

Immune Thrombocytopenia

United States, France, Germany, Hungary, Poland, Russian Federation, Turkey, Ukraine, United Kingdom
Symphogen A/S
Swedish Orphan Biovitrum

Completed

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura

United States, Belgium, Germany, India, Israel, Poland, Romania, Russian Federation, Serbia, Spain, Ukraine, United Kingdom
Novartis Pharmaceuticals

Completed

EXTEND (Eltrombopag Extended Dosing Study) (EXTEND)

Purpura, Thrombocytopaenic, Idiopathic

United Kingdom, Hong Kong, United States, Germany, Italy, Netherlands, Spain, Taiwan, Thailand, Canada, Denmark, Pakistan, Romania, Slovenia, Russian Federation, Slovakia, Sweden, Poland, China, New Zealand, Ukraine, Australia, Austria and more
Amgen

Completed

Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

United States, Canada, Belgium, Czechia, Mexico, Turkey, Australia, Spain, France, Israel, Hungary, South Africa, Poland, Russian Federation, United Kingdom, Brazil, Switzerland
Federal Research Institute of Pediatric Hematology...

Completed

TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID

Primary Immune Deficiency Disorder | Hematopoietic Stem Cell Transplantation

Russian Federation
Principia Biopharma, a Sanofi Company

Recruiting

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) (LUNA 3)

Immune Thrombocytopenia

United States, China, Argentina, Australia, Brazil, Canada, France, Hungary, Israel, Korea, Republic of, Mexico, Russian Federation, Singapore, Spain, Thailand, United Kingdom, Austria, Chile, Germany, Italy, Japan, Netherlands, Norway and more
Federal Research Institute of Pediatric Hematology...

Recruiting

Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

Primary Immunodeficiency Diseases (PID)

Russian Federation
GlaxoSmithKline

Completed

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (PETIT2)

Idiopathic Thrombocytopenic Purpura

Thailand, Israel, Poland, Russian Federation, Spain, Germany, United Kingdom, Taiwan, Hong Kong, Czech Republic, Italy, United States, Argentina
National Research Center for Hematology, Russia

Recruiting

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Primary Mediastinal Lymphoma

Russian Federation
National Research Center for Hematology, Russia

Recruiting

RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

Primary CNS Lymphoma

Russian Federation
Federal Research Institute of Pediatric Hematology...

Unknown

Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.

Interstitial Lymphocytic Lung Disease

Russian Federation
Octapharma

Completed

Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases

Primary Immune Deficiency Disorder

Russian Federation
St. Petersburg State Pavlov Medical University

Completed

PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis

Primary Myelofibrosis | Myeloproliferative Disorders

Russian Federation
Joint-Stock Company North-West Center for Evidence-Based...

Not yet recruiting

The Effectiveness of Peripheral Magnetic Stimulation in Men With Lower Urinary Tract Symptoms

Bladder Hypersensitivity

Russian Federation
AO GENERIUM

Completed

Observational Study of Elizaria® in aHUS Patients

Atypical Hemolytic Uremic Syndrome | aHUS

Russian Federation
Endocrinology Research Centre, Moscow
Russian Science Foundation

Completed

Vitamin D Metabolism in Patients With Endocrine Disorders

Diabetes Mellitus, Type 1 | Primary Hyperparathyroidism | Acromegaly | Pituitary ACTH Hypersecretion

Russian Federation
Viriom

Completed

Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers

HIV Infections

Russian Federation
AO GENERIUM

Completed

Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers

Hereditary Angioedema

Russian Federation
Dmitry Kireev
Pfizer

Completed

Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping Tools (CoTrAST)

HIV Infection

Russian Federation
University of Illinois at Chicago
National Institute on Drug Abuse (NIDA); Prisma Research Center

Completed

Tajik Migrant Health Education Study

HIV Infections | Hepatitis C | Risk Reduction Behavior | Risky Health Behavior

Russian Federation
Federal Research Institute of Pediatric Hematology...

Unknown

A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients

Hematopoietic Stem Cell Transplantation | Wiskott-Aldrich Syndrome | Graft Failure

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021

Burkitt Lymphoma | Diffuse Large B-cell Lymphoma | Primary CNS Lymphoma | Primary Mediastinal Lymphoma | Non-hodgkin Lymphoma,B Cell

Russian Federation
Johns Hopkins Bloomberg School of Public Health
National Institute on Drug Abuse (NIDA); Johns Hopkins University

Completed

RCT of Russian IDU Peer Network HIV Prevention Intervention - 1

HIV Infections

Russian Federation
Boston Medical Center
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Project HERMITAGE: HIV Prevention in Hospitalized Russian Drinkers

HIV Infections

Russian Federation
Federal Research Institute of Pediatric Hematology...

Completed

Videoocular Assessment of Eye Movement Activity in an Ataxia Telangiectasia

Ataxia Telangiectasia | Dysmetria

Russian Federation
Boston Medical Center
National Institute on Drug Abuse (NIDA)

Completed

Linking Infectious and Narcology Care-Part II (LINC-II)

HIV Infection | Drug Use

Russian Federation
St. Petersburg State Pavlov Medical University

Recruiting

Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy

Membranous Nephropathy - PLA2R Induced

Russian Federation
MSD Pharmaceuticals LLC

Completed

ART First-line Treatment Durability in Russia

HIV-1-infection

Russian Federation

Clinical Trials on Primary Immune Thrombocytopenia (ITP) in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations